ROCKAWAY, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic technology company, announced today that it will report financial results for the first quarter ended March 31, 2025, after the close of the market on Wednesday, May 7, 2025.
Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below:
Wednesday, May 7, 4:30 PM EST
Dial-In: (646) 931-3860
Webinar ID: 885 4355 1292
Passcode: 419231
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a commercial stage bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$4.98 |
| Daily Change: | 0.08 1.63 |
| Daily Volume: | 48,474 |
| Market Cap: | US$39.840M |
September 30, 2025 September 29, 2025 September 05, 2025 September 03, 2025 August 06, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
